ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology

RSLS 11.11.2024

Full Press ReleaseSEC FilingsOur RSLS Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
  • 11.14.2024 - RSLS Third Quarter 2024 Earnings Call
  • 11.14.2024 - ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update

Recent Filings

  • 01.21.2025 - S-1 General form for registration of securities under the Securities Act of 1933
  • 01.21.2025 - 8-K Current report
  • 01.15.2025 - S-4/A Registration of securities, business combinations
PDF Version
Approximately $241,000 Grant Will Be Utilized to Conduct Minimally Invasive Laparoscopic Surgical Electrode Implantation Techniques and Long Duration Safety and Blood Glucose Modulation Experiments for the CARSS Project

IRVINE, Calif.,Nov. 11, 2024(GLOBE NEWSWIRE) --ReShape Lifesciences®(Nasdaq: RSLS),the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was awarded an approximately$241,000supplementary grant from theNational Institutes of Health(NIH), with the University of Southern California’sCenter for Autonomic Nerve RecordingandStimulation Systems(CARSS), for the development of the next-generation electrodes for ReShape’s Diabetes Bloc-Stim NeuromodulationTM (DBSNTM) device. The DBSNTM utilizes its proprietary vagus nerve block (vBlocTM) technology platform, combined with vagus nerve stimulation, for the treatment of Type 2 diabetes, a prominent disorder associated with obesity. The supplementary grant will be utilized to conduct minimally invasive laparoscopic surgical electrode implantation techniques as well as long duration safety and blood glucose modulation experiments in a porcine model of diabetes.

“ReShape's DBSNTM device effectively regulates vagal block and stimulation to the liver and pancreas, respectively, resulting in improved blood glucose management. This has been demonstrated through successful glycemic control in a Zucker rat model of Type 2 diabetes and an alloxan treated swine model of Type 2 diabetes, with the support of priorNIHgrants,” statedJonathan Waataja, Ph.D. Director of Research atReShape Lifesciences®. “This non-dilutive supplemental grant, awarded over the course of one year will fund studies to test the safety and efficacy of a the next-generation electrodes which can potentially double the nerve contact area to increase the effectiveness of delivering DBSN signals while reducing power consumption. We look forward to collaborating with CARSS to further the development of the novel DBSNTM device as a potential treatment for diabetes and hypoglycemia.”

“This fourth grant from theNIHbrings our total received awards to$1.15 million, demonstrating the viability of our non-dilutive funding strategy and the NIH’s keen interest in our novel DBSNTM technology and its potential in the global diabetes market,” statedPaul F. Hickey, President and Chief Executive Officer ofReShape Lifesciences®. “With these funds, our team has successfully completed the pre-clinical development of the device, utilizing bioelectronics to regulate insulin production and manage blood glucose levels for the potential treatment of Type 2 diabetes and hypoglycemia. This innovative technology has demonstrated the ability to reduce the reliance on medications for diabetics in a personalized manner, aiming to lower treatment costs and complications associated with poorly controlled blood glucose and medication non-compliance. The effectiveness and potential of a DBSNTM device is reflected, not only by the substantialNIHfunding, but also by the presentation of compelling preclinical evidence at various medical conferences. Backed by a strong intellectual property portfolio of 74 issued or pending patents related to vBloc, glucose control, AI and Bluetooth applications, we remain committed to furthering its development through similarNIHgrants or potential strategic alliances.”

About Diabetes Bloc-Stim NeuromodulationTM DeviceThe Diabetes Bloc-Stim NeuromodulationTM (DBSNTM) system is a novel therapeutic concept that is implanted minimally invasively and delivers bio-electronic neuromodulation of vagus nerve branches that are innervating organs which regulate plasma glucose. The DBSNTM system stimulates vagus celiac fibers of the pancreas to release insulin during stimulation, while blocking the hepatic vagal branch, innervating the liver, to decrease glucose release and decrease insulin resistance following ligation. The DBSNTM system utilizes a proprietary, reversable and adjustable electrical blockade that we believe is key to the future of personalized medicine. We believe the DBSNTM system is superior to both standalone stimulation of the vagus nerve that has shown mixed results, and vagus nerve ligation that has undesirable effects.

AboutReShape Lifesciences®ReShape Lifesciences®is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band®and Lap-Band®2.0 Flex Systems provide minimally invasive, long-term treatment of obesity and are an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim NeuromodulationTM (DBSNTM) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon®balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visitwww.reshapelifesciences.com.

As previously announced ReShape has entered into an asset purchase agreement with Biorad Medisys, Pvt. Ltd., pursuant to which ReShape has agreed to sell substantially all of its assets to Biorad (or an affiliate thereof), including ReShape’s Lap-Band®System, Obalon®Gastric Balloon System and the DBSNTM system (but excluding cash). Therefore, at the closing of the transactions contemplated by the asset purchase agreement, the DBSNTM system will be owned by Biorad.

Forward-Looking Safe Harbor StatementThis press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about our continued development of the DBSNTM system and use of theNIHgrant funds. These and additional risks and uncertainties are described more fully in the company's filings with theSecurities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

CONTACTSReShape Lifesciences Investor Contact:Paul F. HickeyPresident and Chief Executive Officer949-276-7223ir@ReShapeLifesci.com

Investor Relations Contact:Rx Communications GroupMichael Miller917-633-6086mmiller@rxir.com

Primary Logo

Source: ReShape Lifesciences Inc

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com